BioCentury | Sep 27, 2004
Company News

Migragen AG, Morphochem, Schering deal

...Migragen sold their joint rights to a patent application covering Rho kinase inhibitors to SCH. Migragen...
...placebo after eight weeks in a Phase II trial in 84 patients with stable angina. Migragen...
BioCentury | Sep 20, 2004
Company News

Schering in-licenses Rho kinase inhibitor IP

...Morphochem (Munich, Germany) and Migragen (Tuebingen, Germany) sold their joint rights to a patent application covering...
...their joint rights to a patent application covering Rho kinase inhibitors to Schering (FSE:SCH; SHR). Migragen...
...which filed for insolvency last year, was developing Rho kinase inhibitors with Morphochem . The Migragen...
BioCentury | Feb 3, 2003
Company News

Migragen AG, Yale University deal

...to a nerve regeneration technology to develop and market. The parties jointly developed the technology. Migragen...
BioCentury | Sep 30, 2002
Company News

DeveloGen, Migragen AG other research news

...nanomolar concentrations, indicating that RGM can specifically guide axon formation. DeveloGen AG , Gottingen, Germany Migragen...
BioCentury | Sep 9, 2002
Company News

Migragen AG management update

Migragen AG , Tuebingen, Germany Business: Neurological, cancer Hired: Lucio van Rooijen as president and CEO, formerly VP of business development and a director of Aventis S.A .’s Xzillion Proteomics division WIR Staff cancer Neurology...
BioCentury | Sep 6, 2002
Company News

van Rooijen named Migragen CEO

...CNS and cancer play Migragen (Tuebingen, Germany) hired Lucio van Rooijen as president and CEO. van...
BioCentury | Jul 8, 2002
Company News

Migragen AG, Morphochem deal

...Migragen’s targets and cell-based and animal model assays. The partners will jointly own resulting compounds. Migragen...
BioCentury | Jul 3, 2002
Company News

Migragen, Morphochem neurological deal

...technology for identifying small molecules with Migragen 's targets and cell-based and animal model assays. Migragen...
Items per page:
1 - 8 of 8
BioCentury | Sep 27, 2004
Company News

Migragen AG, Morphochem, Schering deal

...Migragen sold their joint rights to a patent application covering Rho kinase inhibitors to SCH. Migragen...
...placebo after eight weeks in a Phase II trial in 84 patients with stable angina. Migragen...
BioCentury | Sep 20, 2004
Company News

Schering in-licenses Rho kinase inhibitor IP

...Morphochem (Munich, Germany) and Migragen (Tuebingen, Germany) sold their joint rights to a patent application covering...
...their joint rights to a patent application covering Rho kinase inhibitors to Schering (FSE:SCH; SHR). Migragen...
...which filed for insolvency last year, was developing Rho kinase inhibitors with Morphochem . The Migragen...
BioCentury | Feb 3, 2003
Company News

Migragen AG, Yale University deal

...to a nerve regeneration technology to develop and market. The parties jointly developed the technology. Migragen...
BioCentury | Sep 30, 2002
Company News

DeveloGen, Migragen AG other research news

...nanomolar concentrations, indicating that RGM can specifically guide axon formation. DeveloGen AG , Gottingen, Germany Migragen...
BioCentury | Sep 9, 2002
Company News

Migragen AG management update

Migragen AG , Tuebingen, Germany Business: Neurological, cancer Hired: Lucio van Rooijen as president and CEO, formerly VP of business development and a director of Aventis S.A .’s Xzillion Proteomics division WIR Staff cancer Neurology...
BioCentury | Sep 6, 2002
Company News

van Rooijen named Migragen CEO

...CNS and cancer play Migragen (Tuebingen, Germany) hired Lucio van Rooijen as president and CEO. van...
BioCentury | Jul 8, 2002
Company News

Migragen AG, Morphochem deal

...Migragen’s targets and cell-based and animal model assays. The partners will jointly own resulting compounds. Migragen...
BioCentury | Jul 3, 2002
Company News

Migragen, Morphochem neurological deal

...technology for identifying small molecules with Migragen 's targets and cell-based and animal model assays. Migragen...
Items per page:
1 - 8 of 8